


CLEAR: **(Canadian LEadership on Antimicrobial Real-life Usage) Registry**

Analysis of IV Meropenem/Vaborbactam Usage in Canada as of May 2026


IV Meropenem/Vaborbactam: <https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=3H4FJ7HA49MDYHY8>

CLEAR (n=10) IV Meropenem/Vaborbactam Surveys by Province




CLEAR (n=10): IV Meropenem/Vaborbactam

Age of Patients



CLEAR (n=10): IV Meropenem/Vaborbactam Infections Treated




cIAI-complicated intra-abdominal infection
CNS-central nervous system infection
VABP-ventilator associated bacterial pneumonia

CANADIAN ANTIMICROBIAL
RESISTANCE ALLIANCE




CLEAR (n=10): IV Meropenem/Vaborbactam Pathogens Treated



ESBL-extended spectrum β -lactamase producing


* CRE-carbapenem resistant Enterobacterales

CLEAR (n=10): IV Meropenem/Vaborbactam Was Patient Bacteremic or in the ICU ?




CLEAR (n=10): IV Meropenem/Vaborbactam

Why Was Meropenem/Vaborbactam Used ?



CLEAR (n=10): IV Meropenem/Vaborbactam

Was IV Meropenem/Vaborbactam Susceptibility Testing Performed ?



Etest = 1 (MIC 4 ug/ml)

CLEAR (n=10): IV Meropenem/Vaborbactam

How Was IV Meropenem/Vaborbactam Dosed / Infused ?

# (%) of Patients	IV Fosfomycin Dose
10 (100%)	2 Grams /2 Grams Q8H

Creatinine clearance measured in 100% (10/10) patients

Infusion time:


- prolonged (≥ 2 hours): 90.0% (9/10)
- Unknown: 10.0% (1/10)

CANADIAN ANTIMICROBIAL
RESISTANCE ALLIANCE



CLEAR (n=10): IV Meropenem/Vaborbactam

Was IV Mero/Vabor Used Along With Another Antibiotic ?




Combination treatment (with IV meropenem/vaborbactam):


- including aztreonam
- including aztreonam + IV fosfomycin
- including daptomycin x 2
- including vancomycin

CLEAR (n=10): IV IV Meropenem/Vaborbactam


Duration of Treatment



CLEAR (n=10): IV Meropenem/Vaborbactam Microbiological Outcome



CLEAR (n=10): IV Fosfomycin Clinical Outcome



Deceased: 1 of 4 (25%) due to infection

CLEAR (n=10): IV Meropenem/Vaborbactam Adverse Effects



Conclusions – CLEAR IV Meropenem/Vaborbactam

1. Meropenem/vaborbactam is used to treat complicated intra-abdominal infections, central nervous system infections, ventilator-associated bacterial pneumonia and bacteremia/sepsis
2. Meropenem/vaborbactam is used as directed treatment for infections caused Gram-negative pathogens (mostly CRE) resistant to other antimicrobials
3. Meropenem/vaborbactam is used due to resistance to other antimicrobials
4. Meropenem/vaborbactam is frequently used with antimicrobial susceptibility testing

Conclusions – CLEAR IV Fosfomycin

5. Meropenem/vaborbactam is frequently combined with other antimicrobial agents (eg. aztreonam for MBL)
6. The most common IV dosage is 2 Grams/2 Grams Q8H and administered using a prolonged infusion (≥ 2 hours)
7. Meropenem/vaborbactam is frequently used for durations >10 days
8. Meropenem/vaborbactam treatment is associated with high rates of microbiological success
9. No adverse events reported in 10 patients

CLEAR: **(Canadian Leadership on Antimicrobial Rea-life Usage) Registry**

Become a CLEAR participant (ggzhanel@pcsinternet.ca)

The CLEAR registry is live, participants receive an email periodically (every 3-4 months) of the most current data as well as links to the **current** registry (eg. **CLEAR - IV Ceftobiprole ENDOCARDITIS, IV Meropenem/Vaborbactam and Pediatric IV fosfomycin**) so that interested ID/MM physicians and ID/Antimicrobial Stewardship pharmacists can enter patient data (prospective or retrospective)

Ceftobiprole ENDOCARDITIS: <https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=JM8JJHLA8N3JDKWA>

Meropenem/Vaborbactam: <https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=3H4FJ7HA49MDYHY8>

PEDIATRIC IV fosfomycin... <https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=FYHJNY4CRLJFN8DL>